HI
CORT icon

Harbour Investments’s Corcept Therapeutics CORT Stock Holding History

Harbour Investments’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2K Buy
23
+19
+475% +$1.15K ﹤0.01% 4022
2026
Q1 		$161 Buy
4
+2
+100% +$75 ﹤0.01% 4468
2025
Q4 		$70 Buy
+2
New +$157 ﹤0.01% 3766
2021
Q2 		– Sell
-421
Closed -$10K – 3792
2021
Q1 		$10K Buy
+421
New +$11.2K ﹤0.01% 2596

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Harbour Investments's CORT Position: Q2 2026 in Review

Harbour Investments increased its Corcept Therapeutics (CORT) stake by 475% in Q2 2026, buying an estimated $1.15K and bringing the position to 23 shares worth $2K. The position accounts for ﹤0.01% of the portfolio, ranked #4022.

Harbour Investments first reported a position in CORT in Q1 2021 and has held it in 4 quarters since. The position peaked at $10K in Q1 2021. 422 funds tracked by Wall St. Rank hold CORT as of Q2 2026.

  • Harbour Investments held 23 shares of Corcept Therapeutics worth $2K as of Q2 2026.
  • Harbour Investments bought 19 Corcept Therapeutics shares in Q2 2026, an estimated $1.15K.
  • Corcept Therapeutics made up ﹤0.01% of Harbour Investments's portfolio in Q2 2026, its #4022 holding.
  • Harbour Investments first reported a position in Corcept Therapeutics in Q1 2021 and has held it in 4 quarters since.
  • Harbour Investments's Corcept Therapeutics position peaked at $10K in Q1 2021.
  • 422 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2026.

Based on Harbour Investments's 13F filing for Q2 2026, filed 12 Aug 2026.